BioNTECH报告将Q2收入翻了一番,计划购买1.25B CureVac用于癌症治疗。 BioNTech reports doubled Q2 revenue, plans $1.25B CureVac acquisition for cancer treatments.

BioNTECH报告说,由于COVID-19疫苗销售量增加,其Q2收入几乎翻了一番,达到2.61亿欧元。 BioNTech reported a nearly doubled Q2 revenue of €261 million, driven by increased sales of its COVID-19 vaccine. 尽管净亏损3.87亿欧元,但该公司看到财务情况有所改善,并保留了2025年的收入准则。 Despite a net loss of €387 million, the company sees improved financials and retained its 2025 revenue guidance. BioNTech还同意以12.5亿美元购买CureVac,以促进以MRNA为基础的癌症治疗,并与Bristol Myers Squibb达成协议,提供111亿美元用于癌症免疫疗法开发。 BioNTech also agreed to acquire CureVac for $1.25 billion to boost mRNA-based cancer treatments, and secured a deal with Bristol Myers Squibb for up to $11.1 billion for cancer immunotherapy development.